Drug Profile


Latest Information Update: 29 May 2000

Price : $50

At a glance

  • Originator Henning Berlin
  • Class Anti-inflammatories; Benzaldehydes; Hydrazones; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Crohn's disease; Ulcerative colitis

Most Recent Events

  • 29 May 2000 Discontinued-Preclinical for Ulcerative colitis in Germany (PO)
  • 29 May 2000 Discontinued-Preclinical for Crohn's disease in Germany (PO)
  • 03 Nov 1998 No-Development-Reported for Crohn's disease in Germany (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top